Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Halken, S; Larenas-Linnemann, D; Roberts, G; Calderón, MA; Angier, E; Pfaar, O; Ryan, D; Agache, I; Ansotegui, IJ; Arasi, S; Du Toit, G; Fernandez-Rivas, M; Geerth van Wijk, R; Jutel, M; Kleine-Tebbe, J; Lau, S; Matricardi, PM; Pajno, GB; Papadopoulos, NG; Penagos, M; Santos, AF; Sturm, GJ; Timmermans, F; van Ree, R; Varga, EM; Wahn, U; Kristiansen, M; Dhami, S; Sheikh, A; Muraro, A.
EAACI guidelines on allergen immunotherapy: Prevention of allergy.
Pediatr Allergy Immunol. 2017; 28(8):728-745
Doi: 10.1111/pai.12807
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Sturm Gunter
- Varga Eva-Maria
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Allergic diseases are common and frequently coexist. Allergen immunotherapy (AIT) is a disease-modifying treatment for IgE-mediated allergic disease with effects beyond cessation of AIT that may include important preventive effects. The European Academy of Allergy and Clinical Immunology (EAACI) has developed a clinical practice guideline to provide evidence-based recommendations for AIT for the prevention of (i) development of allergic comorbidities in those with established allergic diseases, (ii) development of first allergic condition, and (iii) allergic sensitization. This guideline has been developed using the Appraisal of Guidelines for Research & Evaluation (AGREE II) framework, which involved a multidisciplinary expert working group, a systematic review of the underpinning evidence, and external peer-review of draft recommendations. Our key recommendation is that a 3-year course of subcutaneous or sublingual AIT can be recommended for children and adolescents with moderate-to-severe allergic rhinitis (AR) triggered by grass/birch pollen allergy to prevent asthma for up to 2 years post-AIT in addition to its sustained effect on AR symptoms and medication. Some trial data even suggest a preventive effect on asthma symptoms and medication more than 2 years post-AIT. We need more evidence concerning AIT for prevention in individuals with AR triggered by house dust mites or other allergens and for the prevention of allergic sensitization, the first allergic disease, or for the prevention of allergic comorbidities in those with other allergic conditions. Evidence for the preventive potential of AIT as disease-modifying treatment exists but there is an urgent need for more high-quality clinical trials. © 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Child -
- Desensitization, Immunologic - methods
- Desensitization, Immunologic - standards
- Humans -
- Hypersensitivity - prevention & control
- Hypersensitivity - therapy
- Primary Prevention - methods
- Secondary Prevention - methods
- Find related publications in this database (Keywords)
- AGREE II
- allergen immunotherapy
- allergic diseases
- allergic rhinitis
- allergy
- asthma
- atopic dermatitis/eczema
- atopy
- prevention
- sensitization